BMRA

MKT CAP:$7M

Biomerica, Inc.

Market Cap

$7M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$2.18-$0.35 (-13.83%)

Apr 22, 2026

Company Details

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic tes...

CEO

Zackary S. Irani

IPO Date

Sep 7, 1984

Website

www.biomerica.com

Key Metrics TTM

Revenue

$4M

-23.8% YoY

Net Income

-$4M

EPS (Diluted)

-$1.05

Free Cash Flow

-$3M

Revenue / Share

$1.44

Gross Margin

4.3%

Operating Margin

-123.7%

Net Margin

-96.5%

FCF Margin

-73.3%

P/S

1.5x

P/E

—

Earnings Reports

Q3 2026

Apr 13, 2026

NEW

$987.0K-11.8%EPS -$0.44

Q2 2026

Jan 14, 2026

$1M-26.0%EPS -$0.45

Q1 2026

Oct 14, 2025

$1M-23.6%EPS $0.00

FY 2025

Aug 29, 2025

$5M-1.9%EPS -$2.16

Q4 2025

Aug 29, 2025

$749.0K-32.9%EPS -$0.16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 22	$5M	$621.4K	-$2M
Q1 23	$2M	-$55.0K	-$2M
Q2 23	$1M	$351.9K	-$2M
Q3 23	$1M	$120.3K	-$2M
Q4 23	$1M	$28.8K	-$2M
Q1 24	$2M	$412.0K	-$1M
Q2 24	$2M	$325.0K	-$2M
Q3 24	$1M	-$149.0K	-$2M
Q4 24	$1M	$20.0K	-$2M
Q1 25	$2M	$289.0K	-$1M
Q2 25	$2M	$437.0K	-$993.0K
Q3 25	$1M	$19.0K	-$1M
Q4 25	$749.0K	-$244.0K	-$2M
Q1 26	$1M	$424.0K	-$1M
Q2 26	$1M	$51.0K	-$1M
Q3 26	$987.0K	-$44.0K	-$1M

Valuation

Quarter	P/S	P/E
Q4 22	20.9x	—
Q1 23	18.2x	—
Q2 23	26.8x	—
Q3 23	30.2x	—
Q4 23	32.5x	—
Q1 24	29.8x	—
Q2 24	22.3x	—
Q3 24	30.1x	—
Q4 24	14.6x	—
Q1 25	10.7x	—
Q2 25	10.1x	—
Q3 25	9.7x	—
Q4 25	1.7x	—
Q1 26	1.9x	—
Q2 26	1.5x	—
Q3 26	1.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$4M	-$4M
Q1 23	-$2M	-$2M
Q2 23	-$1M	-$1M
Q3 23	-$2M	-$2M
Q4 23	-$962.7K	-$976.8K
Q1 24	-$2M	-$2M
Q2 24	-$842.0K	-$854.0K
Q3 24	-$2M	-$2M
Q4 24	-$1M	-$1M
Q1 25	-$1M	-$1M
Q2 25	-$791.0K	-$791.0K
Q3 25	-$1M	-$1M
Q4 25	-$661.0K	-$661.0K
Q1 26	-$268.0K	-$268.0K
Q2 26	-$991.0K	-$954.0K
Q3 26	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q4 22	$24.4K
Q1 23	$33.6K
Q2 23	$24.5K
Q3 23	$5.8K
Q4 23	$14.1K
Q1 24	$63.0K
Q2 24	$12.0K
Q3 24	$16.0K
Q4 24	$24.0K
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0
Q1 26	$0
Q2 26	$37.0K
Q3 26	$37.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	+403.0%	+175.7%
Q1 23	+29.8%	+32.3%
Q2 23	-68.1%	-45.5%
Q3 23	-85.5%	-64.4%
Q4 23	-79.1%	-58.3%
Q1 24	+4.6%	-20.6%
Q2 24	+5.7%	+0.9%
Q3 24	-8.5%	+9.2%
Q4 24	+0.7%	-10.2%
Q1 25	+5.5%	+7.8%
Q2 25	+4.4%	-17.2%
Q3 25	+10.0%	-22.8%
Q4 25	-32.9%	-12.5%
Q1 26	-23.6%	-21.3%
Q2 26	-26.0%	-1.7%
Q3 26	-11.8%	-1.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$300.8K	5.7%
Q1 23	$303.8K	18.6%
Q2 23	$318.0K	21.5%
Q3 23	$384.0K	34.5%
Q4 23	$179.2K	16.2%
Q1 24	$170.0K	9.9%
Q2 24	$122.0K	7.8%
Q3 24	$341.0K	33.5%
Q4 24	$204.0K	18.3%
Q1 25	$77.0K	4.3%
Q2 25	$155.0K	9.5%
Q3 25	$120.0K	10.7%
Q4 25	$108.0K	14.4%
Q1 26	$460.0K	33.3%
Q2 26	-$210.0K	-17.4%
Q3 26	$135.0K	13.7%

OpEx Breakdown

Quarter	R&D	SG&A
Q4 22	$297.0K	$2M
Q1 23	$361.2K	$2M
Q2 23	$461.9K	$2M
Q3 23	$392.0K	$1M
Q4 23	$368.9K	$1M
Q1 24	$472.0K	$1M
Q2 24	$412.0K	$2M
Q3 24	$343.0K	$2M
Q4 24	$265.0K	$1M
Q1 25	$297.0K	$1M
Q2 25	$257.0K	$1M
Q3 25	$217.0K	$1M
Q4 25	$252.0K	$1M
Q1 26	$212.0K	$1M
Q2 26	$193.0K	$1M
Q3 26	$178.0K	$1M

Revenue Segments

Quarter

Revenue by Geography

Quarter	Asia	Europe	North America	South America	Middle East
Q3 23	$345.0K	$301.0K	$461.0K	$5.0K	—
Q1 26	$670.0K	$305.0K	$318.0K	$2.0K	$85.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$6M	$0	$6M
Q1 23	$6M	$0	$6M
Q2 23	$5M	$0	$5M
Q3 23	$3M	$0	$3M
Q4 23	$10M	$0	$10M
Q1 24	$8M	$0	$8M
Q2 24	$7M	$0	$7M
Q3 24	$5M	$0	$5M
Q4 24	$4M	$0	$4M
Q1 25	$3M	$0	$3M
Q2 25	$2M	$0	$2M
Q3 25	$3M	$0	$3M
Q4 25	$2M	$0	$2M
Q1 26	$3M	$0	$3M
Q2 26	$3M	$0	$3M
Q3 26	$1M	$0	$1M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 22	13M	-1.1%	+2.0%
Q1 23	13M	+3.4%	+5.4%
Q2 23	13M	+2.7%	+6.9%
Q3 23	13M	+0.2%	+5.2%
Q4 23	17M	+24.8%	+32.7%
Q1 24	17M	0.0%	+28.4%
Q2 24	17M	0.0%	+25.0%
Q3 24	17M	0.0%	+24.8%
Q4 24	17M	0.0%	0.0%
Q1 25	17M	0.0%	0.0%
Q2 25	17M	+1.8%	+1.8%
Q3 25	17M	0.0%	+1.8%
Q4 25	10M	-43.3%	-42.3%
Q1 26	3M	-72.8%	-84.3%
Q2 26	3M	+10.2%	-83.0%
Q3 26	3M	+3.5%	-82.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 22	$82.8K	64
Q1 23	$25.6K	64
Q2 23	$23.2K	64
Q3 23	$17.4K	64
Q4 23	$17.9K	62
Q1 24	$27.6K	62
Q2 24	$25.3K	62
Q3 24	$16.4K	62
Q4 24	$17.4K	64
Q1 25	$28.2K	64
Q2 25	$25.6K	64
Q3 25	$17.5K	64
Q4 25	$13.9K	54
Q1 26	$25.6K	54
Q2 26	$22.4K	54
Q3 26	$18.3K	54

Revenue / Employee